ATE413415T1 - Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate - Google Patents

Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate

Info

Publication number
ATE413415T1
ATE413415T1 AT97943460T AT97943460T ATE413415T1 AT E413415 T1 ATE413415 T1 AT E413415T1 AT 97943460 T AT97943460 T AT 97943460T AT 97943460 T AT97943460 T AT 97943460T AT E413415 T1 ATE413415 T1 AT E413415T1
Authority
AT
Austria
Prior art keywords
chains
modified
alginates
materials
polysaccharide
Prior art date
Application number
AT97943460T
Other languages
English (en)
Inventor
David Mooney
Kamal Bouhadir
Wai Wong
Jon Rowley
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE413415T1 publication Critical patent/ATE413415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
AT97943460T 1996-09-19 1997-09-19 Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate ATE413415T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2636296P 1996-09-19 1996-09-19
US2646796P 1996-09-19 1996-09-19
US4156597P 1997-03-21 1997-03-21

Publications (1)

Publication Number Publication Date
ATE413415T1 true ATE413415T1 (de) 2008-11-15

Family

ID=27362748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97943460T ATE413415T1 (de) 1996-09-19 1997-09-19 Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate

Country Status (9)

Country Link
US (1) US6642363B1 (de)
EP (1) EP0927196B1 (de)
JP (2) JP4335316B2 (de)
AT (1) ATE413415T1 (de)
AU (1) AU733716B2 (de)
CA (1) CA2266581C (de)
DE (1) DE69739085D1 (de)
ES (1) ES2317657T3 (de)
WO (1) WO1998012228A1 (de)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
ATE275977T1 (de) 1998-04-13 2004-10-15 Massachusetts Inst Technology Kamm-polymere zur regelung der zelloberflächenwechselwirkung
US7427602B1 (en) * 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
WO1999058656A2 (en) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Sustained dna delivery from structural matrices
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
EP1109919A2 (de) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
JP2002527408A (ja) 1998-10-09 2002-08-27 ミシガン大学 ドラッグデリバリー用ヒドロゲル及び水溶性ポリマーキャリアー
IT1303738B1 (it) * 1998-11-11 2001-02-23 Aquisitio S P A Processo di reticolazione di polisaccaridi carbossilati.
EP1147175A2 (de) * 1999-01-21 2001-10-24 Advanced Medical Solutions Limited Fasern zum wachsen von eukaryotischen zellen
JP4186294B2 (ja) 1999-02-26 2008-11-26 セイコーエプソン株式会社 ポリグルロン酸の製造方法
CA2371462C (en) * 1999-04-22 2009-09-15 Jason C. Schense Modified protein matrices
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2003507440A (ja) * 1999-08-20 2003-02-25 アンドレ・ボウリウ フィブロネクチンを含む固形創傷治癒用組成物
EP1284756B1 (de) * 2000-05-31 2004-09-15 Mnemoscience GmbH Memory-thermoplaste und polymernetzwerke zum gewebeaufbau
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US6748954B2 (en) * 2000-10-27 2004-06-15 The Regents Of The University Of Michigan Drug release from polymer matrices through mechanical stimulation
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
EP1620140B1 (de) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Injizierbare vernetzte polymere zusammensetzungen und deren verwendungen
US7008476B2 (en) * 2003-06-11 2006-03-07 Az Electronic Materials Usa Corp. Modified alginic acid of alginic acid derivatives and thermosetting anti-reflective compositions thereof
WO2005046447A2 (en) * 2003-11-10 2005-05-26 Symphony Medical, Inc. Method to control ventricular rate in atrial fibrillation patients
EP1552818A1 (de) * 2004-01-07 2005-07-13 Shin-Etsu Chemical Co., Ltd. Zusammensetzung, die Freisetzung von Wirkstoffen verlängernd und Zubereitungen mit verlängerter Freisetzung
US20050220882A1 (en) * 2004-03-04 2005-10-06 Wilson Pritchard Materials for medical implants and occlusive devices
DE102004019241A1 (de) * 2004-04-16 2005-11-03 Cellmed Ag Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie
WO2006031388A2 (en) * 2004-08-20 2006-03-23 Hyperbranch Medical Technology, Inc. Dentritic polymers, crosslinked gels, and their uses in orthopedic applications
MX2007004261A (es) 2004-10-12 2007-06-18 Fmc Biopolymer As Sistemas de alginato auto-gelificantes y usos de los mismos.
DE102004055729A1 (de) * 2004-11-18 2006-05-24 Cellmed Ag Herstellung von zwei-oder mehrschichtig aufgebauten Mikrokapseln
US9427496B2 (en) 2005-02-18 2016-08-30 Drexel University Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering
EP1888629B1 (de) * 2005-05-10 2013-04-24 Neoloch Aps Neuritogene peptide
EP1898881B1 (de) * 2005-05-27 2012-04-04 Royer Biomedical, INC. Bioresorbierbare polymermatrizes und verfahren zu ihrer herstellung und verwendung
US20070020755A1 (en) * 2005-07-07 2007-01-25 Teresa Woodruff Stage specific follicle maturation systems
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
HUE051267T2 (hu) 2005-12-13 2021-03-01 Harvard College Sejttranszplantációs állványok
ES2362897T3 (es) * 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
JP2009528437A (ja) * 2006-03-01 2009-08-06 エフエムシー バイオポリマー エイエス 生分解性発泡体
WO2007147014A2 (en) * 2006-06-13 2007-12-21 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
ATE552867T1 (de) * 2006-06-16 2012-04-15 Fmc Biopolymer As Alginatbeschichtete collagenmatrix- zellvorrichtung, herstellungsverfahren dafür und verwendungen davon
BRPI0714386A2 (pt) * 2006-07-14 2012-12-25 Fmc Biopolymer As hidrogel, conta, mÉtodos para produzir um hidrogel ou uma conta, para implantar uma conta ou dispositivo mÉdico implantÁvel e cÉlulas em um paciente, para bloquear vasos sanguÍneos, e para formar um hidrogel, dispositivo mÉdico implantÁvel, formulaÇço de liberaÇço de droga, agente de contraste ou material radioopaco, e, composiÇço terapÊutica embàlica
CA2660300C (en) * 2006-08-09 2014-12-09 Sumitomo Bakelite Co., Ltd. Sugar chain-capturing substance and use thereof
PL2077830T3 (pl) 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
WO2008098220A1 (en) * 2007-02-08 2008-08-14 University Of Washington Biocompatile amino acid anhydride polymers
WO2008098109A2 (en) * 2007-02-08 2008-08-14 Northwestern University Hydrogel compositions
CN101778891B (zh) * 2007-06-13 2013-01-16 Fmc有限公司 涂覆藻酸盐的含多糖凝胶泡沫复合物,其制备方法及其应用
US20100239540A1 (en) * 2007-06-13 2010-09-23 Fmc Corporation Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same
US20100178313A1 (en) * 2007-06-13 2010-07-15 Fmc Corporation Implantable Degradable Biopolymer Fiber Devices
US9770535B2 (en) * 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
ES2322637B1 (es) * 2007-06-26 2010-03-05 Universidad Del Pais Vasco Microparticulas de alginato modificado con rgd como sistema de liberacion de farmacos.
CN101918007B (zh) * 2007-08-28 2014-06-04 Fmc有限公司 延迟的自胶凝藻酸盐体系及其应用
US8246992B2 (en) * 2007-11-01 2012-08-21 Osaka City University β-1,3-glucan-derived polyaldehyde/polyamine hydrogel
IL187707A0 (en) * 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
EP2082755A1 (de) * 2008-01-16 2009-07-29 CellMed AG Monolithische in-situ vernetzte Alginatimplantate
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
US8668863B2 (en) * 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US8790701B2 (en) * 2008-04-28 2014-07-29 Surmodics, Inc. Poly-α(1→4)glucopyranose-based matrices with hydrazide crosslinking
WO2009146456A1 (en) * 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US8252317B2 (en) * 2009-02-26 2012-08-28 General Electric Company Metal alginate hydrogel and articles thereof
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
JP5248676B2 (ja) * 2009-05-22 2013-07-31 サンヨー食品株式会社 不斉酸化反応を有する蛋白質複合体およびその製造方法
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CA2768552A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
PT104879B (pt) * 2009-12-10 2012-10-17 Univ Do Minho Hidrogel de dextrino para aplicações biomédicas
GB0922133D0 (en) 2009-12-17 2010-02-03 Glaxo Group Ltd Composition
US8197849B2 (en) * 2010-02-12 2012-06-12 National Health Research Institutes Cross-linked oxidated hyaluronic acid for use as a vitreous substitute
EP2542230A4 (de) 2010-03-05 2013-08-28 Harvard College Förderung des anwachsens von skelettmuskel-stammzellen durch gleichzeitige verabreichung von vegf und igf-1
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
TWI398275B (zh) * 2010-07-12 2013-06-11 行政院農業委員會農業試驗所 皮膚創傷敷料及其製備方法
WO2012012520A1 (en) * 2010-07-20 2012-01-26 Washburn Therapeutics, Inc. Enhanced binding of pro-inflammatory cytokines by polysaccharide-antibody conjugates
US11202759B2 (en) * 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012048289A1 (en) 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012048283A1 (en) 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
EP2670856B1 (de) * 2011-02-03 2018-06-27 Northeastern University Verfahren und zusammensetzungen zur hochspezifischen erfassung und freisetzung biologischer materialien
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
JP6359966B2 (ja) * 2011-04-28 2018-07-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 最小侵襲投与のための注射可能な予成形される肉眼的三次元スキャフォールド
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
WO2013025763A2 (en) * 2011-08-15 2013-02-21 President And Fellows Of Harvard College Tissue engineering using injectable, oxidized alginate hydrogels
EP2802350B1 (de) 2012-01-13 2017-12-20 President and Fellows of Harvard College Kontrollierte abgabe von tlr-agonisten in strukturierten polymeren vorrichtungen
WO2013112381A2 (en) 2012-01-24 2013-08-01 Bvw Holding Ag New class of anti-adhesion hydrogels with healing aspects
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
EP2931327B1 (de) 2012-12-11 2019-02-13 Board Of Regents, The University Of Texas System Hydrogelmembran zur anhaftungsverhinderung
US9993497B2 (en) 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
BR112015025390A2 (pt) 2013-04-05 2017-08-29 Zylberberg Claudia Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit
EP2796101B1 (de) 2013-04-23 2016-04-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kit zum Herstellen eines vernetzten Gels zum Umschließen von Nierensteinen und/oder Nierensteinfragmenten
ES2577102T3 (es) 2013-04-23 2016-07-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sistema gelificante para eliminar fragmentos de cálculos renales
DE202013012275U1 (de) 2013-04-23 2015-12-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kit zum Herstellen eines vernetzten Gels zum Umschließen von Nierensteinen und/oder Nierensteinfragmenten
DE202013012287U1 (de) 2013-04-23 2016-01-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Gelbildendes System zum Entfernen von Nierensteinfragmenten
AU2013405882B2 (en) 2013-11-25 2017-03-02 Halliburton Energy Services, Inc. Viscosity enhancer
ES2811269T3 (es) 2014-01-31 2021-03-11 Seikagaku Kogyo Co Ltd Agente de reticulación de diamina, cuerpo reticulado de polisacárido ácido y material médico
WO2015148512A1 (en) 2014-03-24 2015-10-01 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US20170119892A1 (en) 2014-04-04 2017-05-04 President And Fellows Of Harvard College Refillable drug delivery devices and methods of use thereof
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
US11065362B2 (en) 2014-06-12 2021-07-20 President And Fellows Of Harvard College Viscoelastic hydrogels with fast stress relaxation
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP3250250A4 (de) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumorale und intratumorale materialien zur krebstherapie
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US10376592B2 (en) 2015-06-29 2019-08-13 University of Pittsburgh—of the Commonwealth System of Higher Education Stapled acid-sensitive endosome disrupting alginates
US9790467B2 (en) 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
EP3821880A1 (de) 2015-10-26 2021-05-19 President and Fellows of Harvard College Oxidierte polysaccharide und verfahren zur verwendung davon
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
MA44490A (fr) * 2016-03-22 2019-01-30 Harvard College Adhésifs biocompatibles et leurs procédés d'utilisation
WO2017165389A2 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Alginate hydrogel compositions
WO2017192753A1 (en) 2016-05-03 2017-11-09 Bvw Holding Ag Multiphase gel
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
MX2019006536A (es) 2016-12-13 2019-08-22 Millennium Pharm Inc Recubrimiento de conformacion de superficies biologicas.
US11591564B2 (en) * 2016-12-16 2023-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Peptide conjugated hydrogel substrate for the maintenance and expansion of human pluripotent stem cells
EP3573624B1 (de) 2017-01-27 2025-03-19 Cornell University Zwitterionisch modifizierte polymere und hydrogele
US11980700B2 (en) 2017-03-08 2024-05-14 Alafair Biosciences, Inc. Hydrogel medium for the storage and preservation of tissue
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR102123508B1 (ko) * 2018-10-01 2020-06-16 한국원자력연구원 전기전도성 마이크로 니들 패치의 제조방법 및 이에 의해 제조된 전기전도성 마이크로 니들 패치
EP3877452A1 (de) * 2018-11-07 2021-09-15 Universiteit Maastricht Biotinten
CA3122567A1 (en) * 2018-12-10 2020-06-18 The Regents Of The University Of California Salivary gland regeneration
CN110201234B (zh) * 2019-06-26 2021-09-03 山东百多安医疗器械股份有限公司 一种组织工程用前列腺细胞微囊及其制备方法
CN110401637B (zh) * 2019-06-28 2021-03-02 中南民族大学 一种命名数据网络中基于名字的信任方法
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
NL2024820B1 (en) * 2020-02-03 2021-09-13 Mosa Meat B V Hydrogels for cultured meat production
US11678579B2 (en) * 2020-04-29 2023-06-13 The University Of Hong Kong Stretchable ionic hydrogel with high thermopower for low-grade heat harvesting
DE102020116108B4 (de) 2020-06-18 2024-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Verfahren zur Herstellung von Trägerpartikeln für die Kultivierung biologischer Zellen, Trägerpartikel und deren Anwendung
CA3190689A1 (en) 2020-08-31 2022-03-03 The Board Of Trustees Of University Of Illinois Alginate-coated mesenchymal stromal and progenitor cells and methods for using the same
CN118829725A (zh) 2021-10-28 2024-10-22 莱尔免疫制药公司 生成细胞的方法
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
AU2022487694A1 (en) * 2022-12-30 2024-10-24 Sigilon Therapeutics, Inc. Modified polysaccharide polymers and related compositions and methods thereof
WO2025072416A1 (en) * 2023-09-29 2025-04-03 Nutrition & Biosciences USA 4, Inc. Polysaccharide derivatives
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1550819A (en) * 1975-06-04 1979-08-22 Nat Res Dev Polymeric support for biogically active materials
DE3370026D1 (en) * 1983-06-15 1987-04-09 Gist Brocades Nv Biologically active conjugates and their preparation and use
EP0391928B1 (de) * 1987-09-28 1993-12-01 La Jolla Cancer Research Foundation Auswahl von zellen mit verbesserten zelladhäsionseigenschaften
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
NO171069C (no) 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
JPH0581A (ja) * 1991-06-21 1993-01-08 Koken Co Ltd 細胞培養担体及び培養方法
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5429821A (en) 1992-05-29 1995-07-04 The Regents Of The University Of California Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
JPH08509956A (ja) 1993-02-12 1996-10-22 マヨ ファウンデーション フォー メディカル エデュケイション アンド リサーチ 凝縮相微小球体組成物および方法
IT1268955B1 (it) 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl Esteri attivi di polisaccaridi carbossilici
JP3107726B2 (ja) * 1994-05-13 2000-11-13 株式会社クラレ 水膨潤性高分子ゲル
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
US5863551A (en) * 1996-10-16 1999-01-26 Organogel Canada Ltee Implantable polymer hydrogel for therapeutic uses

Also Published As

Publication number Publication date
EP0927196A1 (de) 1999-07-07
AU733716B2 (en) 2001-05-24
CA2266581C (en) 2007-03-13
AU4493097A (en) 1998-04-14
JP2009120855A (ja) 2009-06-04
US6642363B1 (en) 2003-11-04
EP0927196B1 (de) 2008-11-05
JP5111416B2 (ja) 2013-01-09
EP0927196A4 (de) 2000-12-13
WO1998012228A1 (en) 1998-03-26
JP2001524136A (ja) 2001-11-27
JP4335316B2 (ja) 2009-09-30
DE69739085D1 (de) 2008-12-18
ES2317657T3 (es) 2009-04-16
CA2266581A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
ATE413415T1 (de) Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
Almany et al. Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures
EP1806367A3 (de) Polysaccharide wie Alginate oder modifizierte Alginate enthaltende Polymere
BRPI0413086A (pt) matriz complexa, utilização da mesma, e processo de preparação de uma matriz biocompatìvel pouco biodegradável
ATE356638T1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
EP0894825A4 (de) Dienpolymerzusammensetzung, verfahren zu deren herstellung und kautschukzusammensetzung die dieselbe enthält
DK0910412T3 (da) Hydrolyserbare hydrogeler til kontrolleret frigørelse
MX2009002653A (es) Derivados de acido hialuronico obtenidos via reticulacion de "quimica modular".
AU2007216998A8 (en) Segmented degradable polymers and conjugates made therefrom
WO2000021572A3 (en) Hydrogels and water soluble polymeric carriers for drug delivery
AU5062099A (en) An antilipemic formulation
RU2010125705A (ru) Гелевые полисахаридные композиции и способы длительной доставки лекарственных средств
EP1613663A4 (de) Vernetzte polysaccharidzusammensetzung
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DE69708304D1 (de) Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
WO2007064772A3 (en) Implantable microbial cellulose materials for various medical applications
ATE346146T1 (de) Fibrinmikrokugeln und deren verwendungen
WO2002085419A3 (en) Bifunctional-modified hydrogels
AU2831900A (en) Stereocomplex hydrogels
ATE469936T1 (de) Modifiziertes polymer und modifizierte polymermembran
AU5376500A (en) Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application
WO2004029137A3 (en) Cross-linked polymer matrices, and methods of making and using same
DK1051158T3 (da) Farmaceutiske præparater i form af polymere mikropartikler fremstillet ved ekstrudering og sfæronisering
DK0889957T3 (da) Subtilisindimer med forbedret aktivitet og fremgangsmåde til fremstilling deraf
BR0009325B1 (pt) composições moldadas de policarbonato modificadas por polìmero de enxerto, uso das mesmas e corpos moldados.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties